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Introduction {#sec1}
============

Intestinal stem cells (ISCs) produce diverse mature cell types. The best characterized and most abundant ISC pool consists of *Lgr5*^+^ cells at the crypt base ([@bib1]). These cells replicate daily, giving rise to highly proliferative transit-amplifying (TA) progenitors, which occupy higher crypt tiers and eventually produce terminally differentiated villus cells (VCs), including absorptive enterocytes and secretory (goblet and enteroendocrine) cells. *Lgr5*^+^ ISCs contribute to all mature VC lineages for months ([@bib1]) and generate "organoids" that self-renew in culture ([@bib14]). Other ISC populations at different crypt positions replicate less frequently, respond to tissue injury, and express markers such as *Bmi1*, *Hopx*, *Lrig1*, and *Tert* ([@bib2]); *Lgr5*^+^ ISCs may co-express the same marker genes ([@bib8], [@bib11]). Indefinite self-renewal and the potential to yield distinct daughter lineages require particular transcriptional programs, but the transcription factors (TFs) that drive them and the associated chromatin states are insufficiently understood. Although knockout mice have implicated several TFs, including ASCL2, KLF5, and YY1, in control of various ISC functions ([@bib12], [@bib13], [@bib22]), their target genes and mechanisms remain unclear, in part because it is difficult to isolate enough ISCs for biochemical studies.

Using RNA sequencing (RNA-seq) to profile transcripts in intestinal VCs and *Lgr5*^+^ ISCs, we observed that *Cdx2*, a homeobox TF gene implicated in gut epithelial development ([@bib4], [@bib5]) and adult enterocyte maturation ([@bib24]), was highly and almost equally expressed in both cell populations. Conditional null mice revealed an autonomous proliferation deficit in *Cdx2*^−/−^ ISCs, and instead of producing mature intestinal cell types, these cells formed undifferentiated cystic structures in vivo and failed to generate proper organoids in culture. Analysis of CDX2 occupancy in wild-type ISCs, integrated with transcriptional changes in purified *Cdx2*^−/−^ ISCs, identified candidate direct target genes and revealed a likely dual role in gene activation and repression. Most CDX2 binding in ISCs, however, occurs in anticipation of gene activity in future cell generations.

Results {#sec2}
=======

Differential Gene Expression in ISCs and VCs {#sec2.1}
--------------------------------------------

To identify gene expression changes during intestinal epithelial differentiation, we isolated *Lgr5*^+^ ISCs from *Lgr5*^EGFP-CreERT2^ knockin mice (*Lgr5*^KI^) ([@bib1]) and mature VCs, comprised mainly of enterocytes. As RNA-seq revealed modest 3′ bias in ISC samples, we applied a 3′ tag counting method to restrict FPKM (fragments per kilobase of exon per million fragments mapped) calculations to reads mapping to the most 3′ 1,000 bp of each gene ([@bib16]). We observed significant differences in 3,317 VC-enriched and 2,889 ISC-enriched transcripts (*Q* \< 0.05, fold change \> 2; [Figure 1](#fig1){ref-type="fig"}A). VC-enriched genes included enterocyte (*Sis*, *Alpi/Akp3*, *Lct*, *Fabp1*) and goblet-cell (*Muc2*, *Tff3*) markers, while genes such as *Lgr5*, *Ascl2*, *Axin2*, *Myc*, and *Olfm4* were enriched in ISCs ([Figure 1](#fig1){ref-type="fig"}A). Genes enriched \>4-fold in ISCs belonged in Gene Ontology terms related to cell-cycle control, protein translation, and DNA replication, while VC-enriched terms included lipid metabolism, membrane transport, and oxidation-reduction ([Figure 1](#fig1){ref-type="fig"}B), indicating that the data are reliable. Genes previously ascribed to alternative ISC populations---*Bmi1*, *Hopx*, *Lrig1*, and *Prom1*---were highly expressed in both *Lgr5*^+^ ISCs and VCs ([Figure 1](#fig1){ref-type="fig"}A), supporting recent reports that these markers are not exclusive ([@bib8], [@bib11]). Levels of *Cdx2*, an intestine-restricted TF gene necessary for enterocyte maturation ([@bib24]), were almost as high in purified ISCs as in VCs ([Figure 1](#fig1){ref-type="fig"}A); immunostaining confirmed CDX2 expression in ISCs ([Figure 1](#fig1){ref-type="fig"}C).

Loss of CDX2 Markedly and Selectively Impairs ISC Proliferation and Differentiation {#sec2.2}
-----------------------------------------------------------------------------------

To investigate a possibly separate CDX2 role in ISCs, we examined *Cdx2*^Fl/Fl^*;Villin-Cre*^ERT2^ mice, where tamoxifen (TAM) deletes *Cdx2* in all small intestine epithelial cells (*Cdx2*^E-Del^ for epithelium deleted; [Figure 1](#fig1){ref-type="fig"}C). Although ISCs with characteristic ultrastructural features were present at the crypt base ([Figure 1](#fig1){ref-type="fig"}D), the number of crypts with at least one KI67^+^ ISC was reduced throughout the *Cdx2*^E-Del^ small intestine, most significantly in the ileum ([Figures 1](#fig1){ref-type="fig"}E and 1F), where CDX2 levels are normally highest ([@bib9]). This defect was confined to crypt base ISCs; TA cells in higher tiers showed a normal mitotic fraction ([Figures 1](#fig1){ref-type="fig"}E and 1F).

*Cdx2*^Fl/Fl^*;Lgr5*^KI^ mice (*Cdx2*^ISC-Del^ for ISC deleted) showed CDX2 loss from all GFP^+^ crypts after TAM treatment ([Figure 2](#fig2){ref-type="fig"}A). As *Lgr5*^KI^ mice are mosaic ([@bib1]), many crypts retained CDX2 in all cells, and because Paneth cells do not express *Lgr5* ([@bib1]) and turn over slowly ([@bib7]), they retained CDX2 ([Figure 2](#fig2){ref-type="fig"}A). In the proximal small intestine, where mosaic *Lgr5*^KI^ expression is highest ([@bib1]), we observed fewer LGR5-GFP^HI^ cells in S-phase and more cells in G1 ([Figure 2](#fig2){ref-type="fig"}B). Thus, independent measures reveal a significant defect in replication of *Cdx2* null ISCs. Because CDX2 is expressed only in epithelial cells and not in the lamina propria, this defect must be cell autonomous.

Intact TA cell replication suggested that early events following ISC differentiation may not require CDX2. To test this possibility, we crossed a *Rosa26*^lox-STOP-lox-YFP^ allele (*R26R*^YFP^ \[[@bib18]\]) onto the *Cdx2*^Fl/Fl^*;Lgr5*^KI^ background to enable lineage tracing. After treating mice with TAM, we followed YFP expression serially ([Figure 2](#fig2){ref-type="fig"}C), noting again that mosaic *Lgr5*^KI^ expression would delete *Cdx2* and activate *Yfp* in a minority of crypts. As TAM induction of the *Lgr5-Cre*^ERT2^ irreversibly marks cells with YFP, continuous *Lgr5* expression is not required to monitor the lineage tracing. Ten days later, YFP was present in crypts and villi in control (*Cdx2*^+/+^*;Lgr5*^KI^*;R26R*^YFP^) and, at slightly lower frequency, in *Cdx2*^ISC-Del^ mice ([Figure 2](#fig2){ref-type="fig"}C). However, starting at 1 month and continuing for at least 6 months after Cre activation, YFP expression in *Cdx2*^ISC-Del^ intestines was confined to crypts and cystic inclusions, and never detected in villi ([Figures 2](#fig2){ref-type="fig"}C, [S1](#mmc1){ref-type="supplementary-material"}A, and S1B). These cysts, similar to those previously noted in *Cdx2*^−/−^ crypts ([@bib19]), showed total absence of CDX2 and of mature VC features such as alkaline phosphatase, which marks enterocytes, or avidity for periodic acid-Schiff or Alcian blue, which marks goblet cells ([Figure 2](#fig2){ref-type="fig"}D). Cells lining the cysts had a cuboidal morphology, with round nuclei ([Figure S1](#mmc1){ref-type="supplementary-material"}C); EZR and NHERF localization indicated intact apico-basal polarity ([Figure S1](#mmc1){ref-type="supplementary-material"}D). LGR5-GFP expression was typically confined to one side of the cysts, near proliferating TA-like cells, which is reminiscent of normal crypt organization, and non-replicating cells commonly were sloughed from the upper cyst wall, collecting as luminal debris ([Figure S1](#mmc1){ref-type="supplementary-material"}E). Thus, *Cdx2*^Del^ ISCs proliferate poorly, and although they spawn replication-competent TA cells, maturation of their progeny is severely impaired. Of note, intestinal crypt cells also express CDX1 ([@bib9]), a homolog with redundant activity in TA cells ([@bib25]). The specific defects in *Cdx2*^−/−^ crypts reveal a crucial, non-redundant requirement in the stem cell compartment.

*Lgr5*^+^ ISCs generate organoid bodies when cultured in defined media ([@bib14]). To test whether *Cdx2* loss affects this property, we treated *Cdx2*^Fl/Fl^*;Villin-Cre*^ERT2^ intestinal crypts with TAM in culture. Eight days later, organoids from control *Cre*^−^ crypts were large and showed crypt-like evaginations, whereas *Cdx2*-deficient crypts formed few organoids; when present, these were small and spherical, with few protrusions, and totally lacked CDX2, but showed signs of multilineage differentiation in the form of mature enterocyte and goblet cell markers ([Figures S1](#mmc1){ref-type="supplementary-material"}F--S1H). Thus, significant deficits in cell replication, lineage tracing, organoid formation, and generation of mature intestinal cells reveal a CDX2 requirement in ISC functions, ostensibly distinct from CDX2's activity in mature enterocytes or its redundant functions with CDX1 in TA cells.

CDX2 Loss in ISCs Affects Genes that Regulate Cell Proliferation {#sec2.3}
----------------------------------------------------------------

To identify genes dysregulated in CDX2 null ISCs, we isolated GFP^+^ cells from *Cdx2*^ISC-Del^ and control (*Cdx2*^+/+^*;Lgr5*^KI^) intestinal crypts after 4 days of TAM exposure. RNA-seq confirmed loss of most transcripts containing *loxP*-flanked exon 2 in *Cdx2*^Del^ ISCs ([Figure S2](#mmc1){ref-type="supplementary-material"}A). In addition, 412 transcripts were decreased and 639 were increased at least 1.5-fold (*Q* \< 0.05; [Figure 3](#fig3){ref-type="fig"}A). Genes with reduced expression were enriched for terms related to mitosis, consistent with reduced ISC replication, whereas genes that increased in expression were enriched for terms related to drug and lipid metabolism ([Figure 3](#fig3){ref-type="fig"}B). Because CDX2 may mediate intestine-specific Wnt signaling ([@bib23]), we assessed the consequences of CDX2 loss on a curated list of 203 intestinal Wnt target genes ([@bib21]). These transcripts showed higher average expression in control ISCs than in VCs, but average expression was unperturbed in *Cdx2*^Del^ ISCs ([Figure 3](#fig3){ref-type="fig"}C); only 24 individual Wnt target genes were significantly affected, with no obvious pattern ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Although 217 CDX2 binding sites contain a TCF/LEF motif ([Figure 3](#fig3){ref-type="fig"}C), the data suggest that CDX2 activity in ISCs is largely Wnt independent, possibly compensated by the partially redundant factor CDX1. We also probed arrays containing 39 phosphorylated receptor tyrosine kinases with protein lysates from purified control and *Cdx2*^Del^ ISCs. Strong phosphorylation signals for the epidermal growth factor receptor (EGFR) and ERBB2 were reproducibly lower in *Cdx2*^Del^ ISCs ([Figure 3](#fig3){ref-type="fig"}D). Together, these findings reveal that CDX2 controls select ISC genes, some of which mediate cell surface events in EGFR signaling. A single dominant target gene is, however, unlikely to explain CDX2 requirements in vivo. We therefore sought to determine features of CDX2 regulation by mapping its binding sites in ISCs.

Gene Targets of CDX2 Regulation in ISCs {#sec2.4}
---------------------------------------

In contrast with \>12,000 sites previously detected in VCs ([@bib26]), chromatin immunoprecipitation sequencing (ChIP-seq) on purified wild-type *Lgr5*^+^ ISCs identified 2,371 regions enriched for CDX2 binding (e.g., [Figure 3](#fig3){ref-type="fig"}E). The distribution of CDX2 binding sites in promoters and distant sites in *Lgr5*^+^ ISCs resembled that in VCs ([Figure 3](#fig3){ref-type="fig"}F); these areas showed evolutionary conservation ([Figure S2](#mmc1){ref-type="supplementary-material"}C), and the CDX2 consensus motif was the most recurring ([Figure 3](#fig3){ref-type="fig"}G). Moreover, binding sites in ISCs coincided with presence of H3K4me2 ([@bib10]) and H3K27ac ([@bib15]) histone marks, indicating that they represent bona fide active *cis*-regulatory elements ([Figures 3](#fig3){ref-type="fig"}E and 3H).

Most CDX2 binding sites in VCs ([@bib26]) gave weak or no signals in *Lgr5*^+^ ISCs ([Figure 4](#fig4){ref-type="fig"}A), reflecting either truly absent binding or the challenges inherent in detecting low-level occupancy. Conversely, at least 60% of CDX2 binding sites in purified ISCs were also evident in mature VCs ([Figures 4](#fig4){ref-type="fig"}A and 4B), likely representing occupancy at genes expressed in both cell types or ISC binding in anticipation of VC activity. The remaining ∼1,000 binding sites in *Lgr5*^+^ ISCs were considerably weaker or absent in VCs ([Figures 4](#fig4){ref-type="fig"}A and 4B) and may represent sites of ISC-specific activity. To distinguish among these possibilities, we first assigned CDX2 binding sites to the nearest gene within 30 kb. Of the 1,156 genes showing at least 1 binding site in ISCs, 883 genes were also occupied in VCs ([Figure 4](#fig4){ref-type="fig"}C). We first approached these findings from the perspective of genes with nearby CDX2 binding ([Figure 4](#fig4){ref-type="fig"}D). The small proportion of genes bound only in ISCs was similar among ISC-enriched and VC-expressed genes, whereas genes bound only in VCs or in both ISCs and VCs were more highly expressed in VCs. Approaching the data next from the perspective of genes differentially expressed in ISCs and VCs ([Figure 4](#fig4){ref-type="fig"}E), we see that villus-expressed genes are enriched for CDX2 binding in both ISCs and VCs. In contrast, genes with unique CDX2 binding in ISCs are distributed across the expression spectrum ([Figure 4](#fig4){ref-type="fig"}E). Notably, genes bound in both ISCs and VCs are highly enriched for "transcriptional activity" (Gene Ontology cluster enrichment score: 3.38) and include *Cdx1/2*, *Gata4/6*, *Hnf4a/g*, *Hnf1b*, *Klf5*, *Vdr*, and *Yy1* ([Figure S2](#mmc1){ref-type="supplementary-material"}D). Thus, much of the CDX2 binding in ISCs persists in differentiated cells, near genes that are highly expressed in the latter. This binding thus precedes future VC activity rather than serving functions unique to ISCs.

Because direct transcriptional targets in ISCs should show both CDX2 binding and perturbed mRNA levels in its absence, we considered ISC binding in the light of differential gene expression in *Cdx2*^ISC-Del^ ISCs. Most CDX2-bound genes were unaffected in transcript levels, implying that CDX2 is dispensable for their regulation. Among the 137 genes with CDX2 binding and altered mRNA levels in *Cdx2*^−/−^ ISCs, 80 genes were increased and 57 were decreased ([Figures 4](#fig4){ref-type="fig"}F--4H and [S3](#mmc1){ref-type="supplementary-material"}). In VCs, by contrast, CDX2 binds almost exclusively at loci that are downregulated upon *Cdx2* loss ([@bib26]). Thus, whereas CDX2 predominantly activates VC genes, in ISCs it may activate some genes and repress others.

Discussion {#sec3}
==========

We demonstrate an early, cell-autonomous role for CDX2 in promoting ISC replication in vivo and *Cdx2*^−/−^ cells' steadily diminished ability to produce differentiated VCs. Previous studies of *Cdx2*^Del^ cysts and organoid cultures have suggested that *Cdx2* loss activates stomach epithelial marker genes and hence compromises intestinal identity ([@bib6], [@bib17], [@bib19]). However, our RNA-seq analysis of *Cdx2*^Del^ ISCs revealed elevated levels of only 2 of 11 common stomach-specific transcripts ([Table S1](#mmc1){ref-type="supplementary-material"}), and we did not detect CDX2 binding near these genes in ISCs. Thus, gastric transdifferentiation does not seem to be a prominent early feature of *Cdx2*^−/−^ ISCs, though other target genes, including transcriptional and epigenetic regulators, may perturb stomach-specific genes over time.

Feedback mechanisms for ISC homeostasis are poorly understood. By revealing different CDX2 requirements in various crypt cell populations, our findings provide useful insights. First, combined loss of CDX1 and CDX2 markedly affects TA cell replication ([@bib25]), but these cells withstand loss of CDX2 alone. Second, the outcome when *Lgr5*^+^ ISCs are incapacitated by CDX2 loss---but remain viable---differs from that when *Lgr5*^+^ ISCs are killed using *Diphtheria* toxin. Whereas reserve Bmi1^+^ ISCs are rapidly recruited into an active role in the latter case ([@bib20]), *Cdx2*^−/−^ cysts persist for months, avoiding replacement by CDX2^+^ cells, such as the progeny of quiescent ISCs in *Cdx2*^ISC-Del^ mice. One possibility is that leaky *Lgr5-Cre* expression in quiescent ISCs triggered deletion of *Cdx2*, which is also required in this ISC pool, but *Lgr5* expression is notably absent in quiescent ISCs in *Lgr5*^KI^ mice ([@bib1], [@bib20]). We therefore favor the alternative explanation that persistent ISCs and TA cells in *Cdx2*^ISC-Del^ intestines are sufficient to avoid the feedback signals that elicit compensatory activity from quiescent ISCs.

This study advances understanding of CDX2 mechanisms in ISC maintenance and differentiation. CDX2 occupies hundreds of genomic sites exclusively in ISCs and thousands of additional sites in VCs. Unlike in VCs, however, CDX2 binding in ISCs correlates poorly with ISC-expressed genes. Instead, much of it overlaps with binding sites in VCs, occurring at genes activated in subsequent cell generations. Moreover, while CDX2 behaves almost exclusively as a transactivator in VCs, it may directly activate or repress ISC genes. This could occur through interactions with different co-factors, alternative post-translational modifications, or differential chromatin access. Studies of other TFs and chromatin in purified ISCs are necessary to resolve these possibilities.

Experimental Procedures {#sec4}
=======================

Mice {#sec4.1}
----

*Cdx2*^Fl/Fl^, *Villin-Cre*^ERT2^, *Lgr5-EGFP-IRES-Cre*^ERT2^, and *Rosa26-lox-STOP-lox-YFP* mice were described previously ([@bib1], [@bib3], [@bib18], [@bib24]). For recombination of conditional alleles, mice were injected intraperitoneally for 4--5 days with 1--2 mg tamoxifen (Sigma). All procedures followed protocols approved by an Institutional Animal Care and Use Committee.

Epithelial Cell Isolation {#sec4.2}
-------------------------

Crypts from the proximal small intestine were isolated by scraping off villi and incubating in 5 mM EDTA. Crypts were trypsinized into a single cell suspension and passed through a FACSAria III instrument (BD Biosciences) to sort single live LGR5-GFP^HI^ cells. Alternatively, intestines were incubated in EDTA and VCs were captured using 70-μm filters.

RNA-Seq {#sec4.3}
-------

More than 10^5^ control ISCs, *Cdx2*^Del^ ISCs, or VCs were collected from single mice, and isolated RNA was sequenced (see the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for RNA isolation, library preparation, sequencing, and analysis protocols). Three biological replicates for each condition were compared, and significantly dysregulated genes were analyzed for Gene Ontology term enrichment.

Histology {#sec4.4}
---------

Intestine segments were fixed overnight in 4% paraformaldehyde at 4°C, and they were dehydrated for paraffin embedding or incubated overnight in 30% sucrose and frozen in optimum cutting temperature (OCT) compound (Tissue-Tek). 5-μm paraffin sections were stained with H&E, alkaline phosphatase, alcian blue, periodic acid-Schiff, or specific antibodies (Ab) to CDX2, KI67, GFP, EZR, or NHERF (more information in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}). 10-μm cryosections were mounted with DAPI to image native YFP.

ChIP-Seq {#sec4.5}
--------

5 × 10^6^ LGR5-GFP^HI^ ISCs were pooled from several mice and cross-linked in 1% formaldehyde at room temperature for 25 min, followed by lysis, sonication, and immunoprecipitation with 3 μg CDX2 Ab (Bethyl Laboratories). See the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"} for ChIP, sequencing, and analysis protocols. CDX2 binding sites were identified from aligned sequencing reads and assigned to the single nearest gene within 30 kb. Published ChIP-seq data were analyzed in parallel.

Additional details of protocols can be found in the [Supplemental Experimental Procedures](#mmc1){ref-type="supplementary-material"}.

Accession Numbers {#app1}
=================

The accession number for all sequencing data reported in this paper is GEO: [GSE70766](ncbi-geo:GSE70766){#intref0010}.
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![Loss of *Cdx2* mRNA Selectively Impairs ISC Proliferation\
(A) RNA-seq data from three biological replicates of *Lgr5*^+^ ISCs and VCs identify modulated genes. Grey, 6,752 genes with comparable expression in both cell types; red, 3,317 VC-enriched genes; blue, 2,889 ISC-enriched genes (\>2-fold; *Q* \< 0.05). Markers of enterocytes or goblet cells (red), *Lgr5*^+^ ISCs (blue), and other ISC populations (green) are highlighted. *Cdx2* is highly expressed in both cell types.\
(B) Gene Ontology clusters of genes with \>4-fold change in VCs and ISCs.\
(C) CDX2 immunohistochemistry (IHC) in control and *Cdx2*^E-Del^ mouse ileum 3 days after final TAM treatment, confirming complete epithelial loss, including ISCs (magnified to right; arrows).\
(D) Electron microscopy of *Cdx2*^E-Del^ ileum confirms the presence of ISCs (blue) among Paneth (P) cells.\
(E) KI67 IHC reveals loss of proliferation in ISCs (magnified in Inset), but not in TA cells.\
(F) Fraction of crypts with at least one KI67^+^ ISC in different regions of control and *Cdx2*^E-Del^ intestines (^∗^p \< 0.01; ^∗∗∗^p \< 0.0001; t test). The average number of KI67^+^ TA cells is not significantly altered. At least 30--50 crypts were counted in each of at least four biological replicates.\
Scale bars represent 50 μm (C and E), 20 μm (inset in E), and 2 μm (D).](gr1){#fig1}

![CDX2 Is Required for *Lgr5*^+^ ISC Proliferation and Differentiation\
(A) Serial tissue sections from control and *Cdx2*^ISC-Del^ intestines 4 days after TAM, showing CDX2 loss in patches of LGR5-GFP-Cre^+^ crypts (dashed areas magnified to right). CDX2 is retained in some Paneth cells in these crypts (arrows).\
(B) Representative cell-cycle analysis of *Lgr5*^+^ ISCs from control and *Cdx2*^ISC-Del^ proximal small bowel. Flow cytometry of *Cdx2*^Del^ ISCs stained with Hoechst dye reveals accumulation in G1, with a reduced S-phase fraction.\
(C) *Cdx2*^Fl/Fl^*;Lgr5*^KI^*;R26R*^YFP^ and control mice were injected with TAM for 5 days and examined at the indicated times. YFP fluorescence at 10 days indicates that traced *Cdx2*^Del^ crypts retain some ability to contribute to villi. At 90 days, tracing in *Cdx2*^ISC-Del^ intestines is confined to cysts (asterisk) and unproductive crypts.\
(D) H&E staining of the cysts shows luminal debris. IHC confirms that traced cysts lack CDX2 and are surrounded by CDX2^+^ crypts that did not express the *Lgr5*^KI^ allele. Alkaline phosphatase (AP), periodic acid-Schiff (PAS), and Alcian blue (AB) staining show absence of mature enterocytes and goblet cells in the cystic structures.\
Scale bars represent 30 μm (A and D) and 50 μm (C). See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Genes Perturbed by CDX2 Loss and Delineation of CDX2 Binding in ISCs\
(A) RNA-seq data from isolated control and *Cdx2*^Del^ ISCs, using three biological replicates. 639 transcripts are elevated in *Cdx2*^−/−^ ISCs (green), and 412 transcripts are reduced (blue). Grey, genes with \<1.5-fold change or *Q* \> 0.05.\
(B) Gene Ontology cluster enrichment among genes reduced or increased in *Cdx2*^Del^ ISCs.\
(C) Average RNA-seq FPKM values of 203 intestinal Wnt target genes in control VCs and ISCs and in *Cdx2*^Del^ ISCs. Significance was assessed by a t test. Bottom: the TCF4 motif found in 217 CDX2 binding sites.\
(D) Phospho-receptor tyrosine kinase arrays probed with lysates from purified control or *Cdx2*^Del^ ISCs. Signals for pEGFR and pERBB2 are reduced in *Cdx2*^Del^ ISCs.\
(E) ChIP-seq signals for CDX2, H3K4me2, and H3K27ac near the *Oat* and *Magohb* genes; the y axis represents aligned ChIP-seq tag counts.\
(F) Distribution of CDX2 binding sites among genomic regions is similar in ISCs and VCs.\
(G) The consensus CDX2 motif is the most enriched (Z score: −41.34) in CDX2-bound sites.\
(H) Heatmaps of ChIP signals for CDX2, H3K4me2, and H3K27ac around CDX2 binding sites in purified ISCs. Right: overlap of CDX2 binding sites with called H3K4me2 and H3K27ac peaks, which underestimate the overlap evident in heatmaps.\
See also [Figure S2](#mmc1){ref-type="supplementary-material"} and [Table S1](#mmc1){ref-type="supplementary-material"}.](gr3){#fig3}

![Contrasting Features of CDX2 Binding in ISCs and VCs\
(A) Number of CDX2 binding sites identified exclusively in ISCs (blue), only in VCs (red), or in both cell types with ≥1-bp overlap (purple).\
(B) Illustrative data traces for CDX2 binding sites of each class (arrows). y axis, ChIP-seq tag counts; x axis: genome coordinates.\
(C) Among the 1,156 genes that bind CDX2 within 30 kb in ISC, 273 are bound only in ISCs and 883 are also bound in VCs.\
(D) Genes bound only in VCs (red) or in both VCs and ISCs (purple) are mostly expressed in VCs (^∗∗∗^p \< 0.0001; χ^2^ test); genes bound only in ISCs (blue) are not enriched for expression in either compartment.\
(E) Genes ordered by the degree of differential expression in ISCs and VCs (\>2-fold, *Q* \< 0.05, from data in [Figure 1](#fig1){ref-type="fig"}A) were binned into groups of 100 (blue--red heatmap). Yellow heatmaps represent average number of CDX2 binding sites in VCs only, in ISCs only, or in both populations within 30 kb of genes in each bin, normalized for average CDX2 binding across all expressed genes.\
(F) CDX2 binds near similar proportions of genes (p = 0.57, Fisher's exact test) that show reduced or increased transcript levels in *Cdx2*^−/−^ ISCs.\
(G) Genes ordered by the degree of differential expression in *Cdx2*^Del^ versus control ISCs (from data in [Figure 3](#fig3){ref-type="fig"}A) were binned into groups of 25 (blue--green heatmap). Below: average number of CDX2 binding sites in ISCs within 30 kb of the genes in each bin, divided by the average CDX2 binding across all expressed genes.\
(H) CDX2 binding data at representative upregulated (*Hmgcs2* and *Hpgd*) and downregulated (*Fgfpb1* and *Vdr*) genes. Right: heatmap of corresponding RNA-seq data.\
Scale bars represent 1 kb (green line in B) and 5 kb (H). See also [Figures S2](#mmc1){ref-type="supplementary-material"} and [S3](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}
